The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 9-16 , 22 March 2004

Inflammation and atherosclerosis: role of C-Reactive protein in risk assessment

  • Peter Libby, MD

      Affiliations

    • Brigham and Women's Hospital, Boston, Massachusetts, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Peter Libby, MD, Donald W. Reynolds Cardiovascular Clinical Research Center, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, Massachusetts 02115, USA.
    • ,
  • Paul M Ridker, MD, MPH

      Affiliations

    • Brigham and Women's Hospital, Boston, Massachusetts, USA

References 

  1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  3. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996;124(suppl):S1–S9
  4. Greenland P, Knoll MD, Stamler J, et al.  Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891–897
  5. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454
  6. Libby P, Ridker PM. Novel inflammatory markers of coro-nary risk (theory versus practice). Circulation. 1999;100:1148–1150
  7. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  8. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  9. Ridker PM, Rifai N, Rose L. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  10. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events (an 8-year follow-up of 14,719 initially healthy American women). Circulation. 2003;107:391–397
  11. Ridker PM. Evaluating novel cardiovascular risk factors (can we better predict heart attacks?). Ann Intern Med. 1999;130:933–937
  12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  13. Pearson TA, Mensah GA, Alexander RW, et al.  Markers of inflammation and cardiovascular disease. Application to clinical and public health practice (a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association). Circulation. 2003;107:499–511
  14. Ridker PM, Rifai N, Clearfield M, et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965
  15. Olsson AG, McTaggart F, Raza A. Rosuvastatin (a highly effective new HMG-CoA reductase inhibitor). Cardiovasc Drug Rev. 2002;20:303–328
  16. Jones PH, Davidson MH, Stein EA, et al.  STELLAR Study [Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin] Group   Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR) trial. Am J Cardiol. 2003;92:152–160
  17. Ridker PM  Jupiter Study Group . Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein (rationale and design of the JUPITER trial). Circulation. 2003;108:2292–2297

PII: S0002-9343(04)00072-5

doi: 10.1016/j.amjmed.2004.02.006

The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 9-16 , 22 March 2004

Article Tools

* Image Usage & Resolution